Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma

Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma

Pancreatic cancer is a leading cause of cancer mortality and is projected to become the second-most common cause of cancer mortality in the next decade. While gene-wide association studies and next generation sequencing analyses have identified molecular patterns and transcriptome profiles with prog...

Full description

Bibliographic Details
Main Authors: Cristina Di Giorgio, Antonio Lupia, Silvia Marchianò, Martina Bordoni, Rachele Bellini, Carmen Massa, Ginevra Urbani, Rosalinda Roselli, Federica Moraca, Valentina Sepe, Bruno Catalanotti, Elva Morretta, Maria Chiara Monti, Michele Biagioli, Eleonora Distrutti, Angela Zampella, Stefano Fiorucci
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Cells
Subjects:
LIF/LIFR axis
pancreatic cancer
mifepristone
cyclins
cell cycle
gemcitabine
Online Access:https://www.mdpi.com/2073-4409/11/21/3482

Internet

https://www.mdpi.com/2073-4409/11/21/3482

Similar Items